Vaccines & Biodefense

In the U.S., the recommended immunization series prevents approximately 33,000 deaths each year. Advancements in biotechnology have made it possible to produce vaccines that cannot transmit a virus or bacterium. This method has helped create more than 20 new vaccines against infectious agents, improved existing vaccines, and increased the amount of vaccine that can be produced.

Coronavirus
Biotech Response to COVID-19

As the threat of the novel coronavirus continues to grow globally, innovative biopharmaceutical companies are ramping up efforts to study the virus and develop vaccines and cures to protect individuals from contracting the virus.

Blog Posts
Covid Vaccine
March 11, 2022
Two years ago, the World Health Organization (WHO) declared COVID-19 a “pandemic.” We look back at key activities from BIO and the biopharmaceutical industry—and where we go from here.
Support Ukraine
March 8, 2022
Adding to the wide-scale human suffering across Ukraine, Russia’s unprovoked invasion of Ukraine is causing a major disruption to both medical as well as agricultural supply chains in the region and worldwide. As…
heart disease
February 24, 2022
Heart disease is the leading cause of death in America. During American Heart Month, we explore how to improve cardiovascular disease outcomes. “Heart disease costs our healthcare system $216 billion dollars annually,…
Press Releases
May 12, 2022
The White House today hosted world leaders and key public and private sector partners at the second Global COVID-19 Summit, a virtual event. Following the conversation, Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), made the…
May 4, 2022
The House Energy & Commerce Committee today unveiled a new package for the Prescription Drug User Fee Act (PDUFA). After the release, BIO’s Chief Science Officer, Cartier Esham, made the following remarks:  "For more than thirty years, the FDA user fee programs have shown tremendous…
April 8, 2022
Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS’s) National Coverage Determination (NCD) to restrict coverage for drugs used to treat patients…
Letters, Comments & Testimony
May 5, 2022
We are writing on behalf of the Biotechnology Innovation Organization (BIO) to provide comments on the Federal Trade Commission’s (FTC’s or the Commission’s) Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and…
April 21, 2022
The Biotechnology Innovation Organization (BIO) welcomes the opportunity to provide comments on the proposed Rules for the Implementation of Regulations on Management of Human Genetic Resources (HGR). BIO acknowledges the efforts of the Division of Science and Technology for Social Development of…
April 1, 2022
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the Oregon Health Authority’s (OHA) proposed Oregon Health Plan §1115 Demonstration Waiver Application (Waiver Application), which among other things, would be a waiver of compliance with essential provisions…
Join BIOAction
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.